相似文献
1
There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment.
Vet Comp Oncol. 2021 Sep;19(3):420-427. doi: 10.1111/vco.12744. Epub 2021 Jul 18.
2
Immunotherapy for canine cancer--is it time to go back to the future?
J Small Anim Pract. 2015 Apr;56(4):229-41. doi: 10.1111/jsap.12336. Epub 2015 Feb 23.
3
Adoptive cell transfer: new perspective treatment in veterinary oncology.
Acta Vet Scand. 2018 Oct 11;60(1):60. doi: 10.1186/s13028-018-0414-4.
4
Cancer Immunotherapies.
Vet Clin North Am Small Anim Pract. 2019 Sep;49(5):881-902. doi: 10.1016/j.cvsm.2019.04.010. Epub 2019 Jun 8.
5
Mesenchymal stem cells: a potential therapy for canine atopic dermatitis?
Vet Rec. 2018 Dec 1;183(21):651-653. doi: 10.1136/vr.k4985.
6
Cancer immunotherapy.
Vet Clin North Am Small Anim Pract. 2010 May;40(3):507-18. doi: 10.1016/j.cvsm.2010.01.002.
7
Translational History and Hope of Immunotherapy of Canine Tumors.
Clin Cancer Res. 2024 Oct 1;30(19):4272-4285. doi: 10.1158/1078-0432.CCR-23-2266.
8
Immunotherapy for Dogs: Running Behind Humans.
Front Immunol. 2018 Feb 5;9:133. doi: 10.3389/fimmu.2018.00133. eCollection 2018.
9
Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?
Vet Comp Oncol. 2020 Dec;18(4):447-470. doi: 10.1111/vco.12595. Epub 2020 Apr 27.
10
Evidence-based integrative medicine in clinical veterinary oncology.
Vet Clin North Am Small Anim Pract. 2014 Sep;44(5):831-53. doi: 10.1016/j.cvsm.2014.06.002.
引用本文的文献
1
Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application.
J Med Virol. 2025 Jun;97(6):e70447. doi: 10.1002/jmv.70447.
2
Limited Clinical Efficacy with Potential Adverse Events in a Pilot Study of Autologous Adoptive Cell Therapy in Canine Oral Malignant Melanoma.
Vet Sci. 2024 Mar 28;11(4):150. doi: 10.3390/vetsci11040150.
本文引用的文献
1
Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.
Clin Cancer Res. 2021 Jun 1;27(11):3005-3016. doi: 10.1158/1078-0432.CCR-21-0315. Epub 2021 Mar 22.
2
Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats.
Vet Comp Oncol. 2021 Jun;19(2):311-352. doi: 10.1111/vco.12677. Epub 2021 Feb 18.
3
Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.
J Vet Intern Med. 2020 Sep;34(5):2056-2067. doi: 10.1111/jvim.15852. Epub 2020 Jul 10.
4
Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Vet Comp Oncol. 2020 Dec;18(4):739-752. doi: 10.1111/vco.12602. Epub 2020 Jun 1.
5
Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer.
PLoS One. 2020 Feb 21;15(2):e0224775. doi: 10.1371/journal.pone.0224775. eCollection 2020.
6
Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.
J Clin Med. 2019 Oct 27;8(11):1802. doi: 10.3390/jcm8111802.
7
Cellular Immunotherapy of Canine Cancer.
Vet Sci. 2018 Dec 6;5(4):100. doi: 10.3390/vetsci5040100.
8
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5.
9
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.
Mol Ther Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002. eCollection 2018 Dec 21.
10
Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
J Immunother Cancer. 2017 Dec 19;5(1):98. doi: 10.1186/s40425-017-0305-7.
Zotero 插件